Molecular basis and clonal evolution of myeloproliferative neoplasms

Haematologica

Volumn 95, Issue 4, 2010, Pages 526-529

  Jäger, Roland ^a   Kralovics, Robert ^a,b  

^a ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CBL PROTEIN; DIOXYGENASE; NEUROFIBROMIN; PROTEIN TET2; UNCLASSIFIED DRUG;

CLONE; EDITORIAL; GENE INACTIVATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HEMATOLOGIC MALIGNANCY; HEMATOPOIESIS; HUMAN; MICROARRAY ANALYSIS; MOLECULAR EVOLUTION; MUTATIONAL ANALYSIS; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; NONHUMAN; PATHOGENESIS; PHENOTYPE; POLYCYTHEMIA VERA; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTOSIS;

CHROMOSOME ABERRATIONS; HUMANS; MYELOPROLIFERATIVE DISORDERS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 77950632087     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.019570     Document Type: Editorial

References (31)

1. Stegelmann F, Bullinger L, Griesshammer M, Holzmann K, Habdank M, Kuhn S, et al. High-resolution single-nucleotide polymorphism array-profiling in myeloproliferative neoplasms identifies novel genomic aberrations. Haematologica. 2010;95(4)666-9.
2. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434(7037):1144-8.
3. Kralovics R, Passamonti F, Buser A, Teo S, Tiedt R, Passweg J, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-90.
4. Levine R, Wadleigh M, Cools J, Ebert B, Wernig G, Huntly B, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7(4):387-97.
5. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Acquired mutation of the tyrosine kinase JAK2 in human myelo- proliferative disorders. Lancet. 2005;365(9464):1054-61.
6. Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythro- cytosis. N Engl J Med. 2007;356(5):459-68.
7. Pietra D, Li S, Brisci A, Passamonti F, Rumi E, Theocharides A, et al. Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)- negative myeloproliferative disorders. Blood. 2008;111(3):1686-9.
8. Kralovics R. Genetic complexity of myeloproliferative neoplasms. Leukemia. 2008;22(10):1841-8.
9. Tiedt R, Hao-Shen H, Sobas MA, Looser R, Dirnhofer S, Schwaller J, et al. Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood. 2008;111(8):3931-40.
10. Kralovics R, Skoda RC. Molecular pathogenesis of Philadelphia chro- mosome negative myeloproliferative disorders. Blood Rev. 2005;19(1): 1-13.
11. Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, Masse A, et al. Mutation in TET2 in myeloid cancers. N Engl J Med. 2009;360(22):2289-301.
12. Grand F, Hidalgo-Curtis C, Ernst T, Zoi K, Zoi C, McGuire C, et al. Frequent CBL mutations associated with 11q acquired uniparental dis- omy in myeloproliferative neoplasms. Blood. 2009;113(24):6182-92.
13. Tefferi A, Pardanani A, Lim KH, Abdel-Wahab O, Lasho TL, Patel J, et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia. 2009;23(5):905-11.
14. Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, Massé A, et al. Mutation in TET2 in myeloid cancers. N Engl J Med. 2009;360(22):2289-301.
15. Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H, Brudno Y, et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science. 2009;324(5929): 930-5.
16. Sanada M, Suzuki T, Shih LY, Otsu M, Kato M, Yamazaki S, et al. Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms. Nature. 2009;460(7257):904-8.
17. Schmidt MH, Dikic I. The Cbl interactome and its functions. Nat Rev Mol Cell Biol. 2005;6(12):907-18.
18. Reynolds RM, Browning GG, Nawroz I, Campbell IW. Von Recklinghausen's neurofibromatosis: neurofibromatosis type 1. Lancet. 2003;361(9368):1552-4.
19. Bollag G, Clapp DW, Shih S, Adler F, Zhang YY, Thompson P, et al. Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nat Genet 1996;12(2):144-8.
20. Birnbaum RA, O'Marcaigh A, Wardak Z, Zhang YY, Dranoff G, Jacks T, et al. Nf1 and Gmcsf interact in myeloid leukemogenesis. Mol Cell. 2000;5(1):189-95.
21. Balgobind BV, Van Vlierberghe P, van den Ouweland AM, Beverloo HB, Terlouw-Kromosoeto JN, van Wering ER, et al. Leukemia-associ- ated NF1 inactivation in patients with pediatric T-ALL and AML lack- ing evidence for neurofibromatosis. Blood. 2008;111(8):4322-8.
22. Olcaydu D, Harutyunyan A, Jager R, Berg T, Gisslinger B, Pabinger I, et al. A common JAK2 haplotype confers susceptibility to myelopro- liferative neoplasms. Nat Genet. 2009;41(4):450-4.
23. Schaub FX, Jager R, Looser R, Hao-Shen H, Hermouet S, Girodon F, et al. Clonal analysis of deletions on chromosome 20q and JAK2-V617F in MPD suggests that del20q acts independently and is not one of the predisposing mutations for JAK2-V617F. Blood. 2009;113(9):2022-7.
24. Buxhofer-Ausch V, Gisslinger H, Berg T, Gisslinger B, Kralovics R. Acquired resistance to interferon alpha therapy associated with homozygous MPL-W515L mutation and chromosome 20q deletion in primary myelofibrosis. Eur J Haematol. 2009;82(2):161-3.
25. Beer PA, Jones AV, Bench AJ, Goday-Fernandez A, Boyd EM, Vaghela KJ, et al. Clonal diversity in the myeloproliferative neoplasms: inde- pendent origins of genetically distinct clones. Br J Haematol. 2009;144(6):904-8.
26. Saint-Martin C, Leroy G, Delhommeau F, Panelatti G, Dupont S, James C, et al. Analysis of the ten-eleven translocation 2 (TET2) gene in familial myeloproliferative neoplasms. Blood. 2009;114(8):1628-32.
27. Beer PA, Delhommeau F, Lecouedic JP, Dawson MA, Chen E, Bareford D, et al. Two routes to leukemic transformation following a JAK2 mutation-positive myeloproliferative neoplasm. Blood. 2009. Epub ahead of print.
28. Grand FH, Hidalgo-Curtis CE, Ernst T, Zoi K, Zoi C, McGuire C, et al. Frequent CBL mutations associated with 11q acquired uniparental dis- omy in myeloproliferative neoplasms. Blood. 2009;113(24):6182-92.
29. Jones AV, Chase A, Silver RT, Oscier D, Zoi K, Wang YL, et al. JAK2 haplotype is a major risk factor for the development of myeloprolifer- ative neoplasms. Nat Genet. 2009;41(4):446-9.
30. Kilpivaara O, Mukherjee S, Schram AM, Wadleigh M, Mullally A, Ebert BL, et al. A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. Nat Genet. 2009;41(4):455-9.
31. Olcaydu D, Skoda RC, Looser R, Li S, Cazzola M, Pietra D, et al. The 'GGCC' haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera. Leukemia 2009;23(10):1924-6.